Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with acute myeloid leukemia (a type of blood cancer) that has not yet been treated, though some limited prior treatments are allowed (confirm with trial site).
- People aged 50 years or older. People under 50 who are not suitable for standard intensive chemotherapy may also be considered after discussion with the lead researcher.
- People whose liver is working well enough, shown by blood test results within certain limits — unless any abnormal results are thought to be caused by the leukemia itself.
- People whose kidneys are working well enough, shown by blood test results within certain limits.
- People who are generally well enough to carry out basic daily activities (assessed using a standard health scale where 0 means fully active and 2 means able to care for oneself but unable to work).
- Women who could become pregnant must have a negative pregnancy test within one week before joining the trial.
- People who are able to understand what the trial involves and are willing to sign a consent form before enrolling.
Who may not be able to join:
- Women who are pregnant, as the treatment used in this trial carries risks of harm to an unborn baby. Women who are breastfeeding are also excluded due to potential risks to the infant.
- People who have a serious uncontrolled illness, such as an active uncontrolled infection, certain heart conditions, or a mental health or personal situation that would make it difficult to follow the trial requirements.
- People who have had a known allergic reaction to any of the medicines used in this trial.
- Men and women who are able to have children and are not willing to use contraception during the trial.
- People who have previously been treated with a medicine called venetoclax.
- People whose blood cancer has been specifically identified as acute promyelocytic leukemia (a particular subtype, also called AML-M3).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tapan M Kadia, M.D. Anderson Cancer Center
Phone: 713-563-3534
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of complete response (CR/complete response with incomplete recovery [CRi])
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.